Key terms: Molecular Imaging, Drug Delivery, Nanotechnology, Biotechnology
2017 Hagemeyer group. L-R: Ms Shweta Jagdale, Ms Hannah Pearce, Dr Karen Alt, Ms Edwina Jap, Mr Joshua Chan, Dr Christoph Hagemeyer, Dr Thomas Bonnard, Ms Jaclyn Lange, Mr Anand Jayapadman, Dr Ting-Yi Wang. Absent: Ms Rania Hashad.
Our main theme is the development of "biobetter" antibodies with added functionality for the treatment of thrombosis and inflammation. Using specifically modified recombinant antibodies we can deliver small molecules, therapeutic oligos and proteins with high precision and reduced adverse effects. We can achieve this with a new bio-enzymatic conjugation method allowing site-specific attachment of nanosized delivery scaffolds without affecting antibody function. We are also active in the molecular imaging area. Using targeted natural nanoparticles we would like to significantly increase the number of imaging labels per antibody in MRI and PET/SPECT as well as photoacoustic and fluorescence imaging. This can increase the detection limit of current approaches.
Projects and opportunities
- Targeted virus particles for gene therapy
- Antibody drug conjugates for cancer treatment
- Single-chain antibody-targeted nanoparticles for therapy and diagnosis
- Recombinant agents for efficient and safe anticoagulation
For current project opportunity descriptions please visit our honours page
Selected publications 2011-2015
- Gunawan ST, Kempe K, Bonnard T, Cui J, Alt K, Wang X, Westein E, Such GK, Peter K, Hagemeyer CE, Caruso F (2015) Multifunctional thrombin-activatable polymer capsules for specific targeting to activated platelets. Advanced Materials 27:5153-7.
- Alt K, Paterson BM, Westein E, Rudd S, Poniger SS, Jagdale S, Ardipradja K, Connell TU, Krippner GY, Nair AKN, Wang X, Tochon-Danguy HJ, Donnelly PS, Peter K, Hagemeyer CE (2015) A versatile approach for the site-specific modification of recombinant antibodies using a combination of enzyme mediated bioconjugation and ‘click chemistry’. Angewandte Chemie International Edition 54:7515-9.
- Hagemeyer CE, Alt K, Johnston AP, Such GK, Ta HT, Leung MK, Prabhu S, Wang X, Caruso F, Peter K (2015). Particle generation, functionalization and sortase A-mediated modification with targeting of single-chain antibodies for diagnostic and therapeutic use. Nature Protocols 10:90-105.
- Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, Alt K, Huang D, Jia F, Ahrens I, Medcalf RL, Peter K, Hagemeyer CE (2014). Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circulation Research 114:1083-93.
- Ta HT, Prabhu S, Leitner E, Jia F, von Elverfeldt D, Jackson K, Heidt T, Nair A, Pearce H, von Zur Muhlen C, Wang X, Peter K, Hagemeyer CE (2011). Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circulation Research 109, 365.
- NHMRC project grant: APP1098867 (2016-18): Novel targeted PEG nanoparticles for cancer treatment and monitoring. PIs: Alt, Paterson
- NHMRC development grant: APP1113743 (2016-17): Preclinical development of a therapeutic anticancer antibody to c-Met . PIs: Johns, Hagemeyer
- NHMRC project grant: APP1078118 (2015-17): Delivering nanoparticles to prevent rupture of unstable
arterial plaques. PI: Hagemeyer
- JDRF project grant: Project 201301746 (2016-2018): Smart insulin delivery with targeted glucose responsive nanomaterials. PIs: Hagemeyer, Caruso, Cooper, Shaw, Allen